GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting
Stock Information for GlycoMimetics Inc.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.